This trial is looking at whether a less expensive and more readily available diagnostic modality, namely CESM, is as effective as MRI in predicting the response of a malignant breast tumor to neoadjuvant chemotherapy and the chances of achieving a pCR.
2 Primary · 0 Secondary · Reporting Duration: Cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.
100 Total Participants · 1 Treatment Group
Primary Treatment: Angiomammography · No Placebo Group · N/A
Age 18+ · Female Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: